DNA疫苗pRSC-gD.gC-IL-21的构建及其预防HSK的动物实验初步研究-东南大学学报医学版

DNA疫苗pRSC-gD.gC-IL-21的构建及其预防HSK的动物实验初步研究

单位：1. 东南大学医学院眼科学系, 江苏南京 210009;
2. 江苏省泰州市人民医院眼科, 江苏泰州 225300;
3. 南京大学医学院附属鼓楼医院眼科, 南京宁益眼科中心, 江苏南京 210008

分类号：R392.11

出版年·卷·期（页码）：2016·35·第六期（932-938）

摘要：

目的：构建DNA疫苗pRSC-gD.gC-IL-21，探讨其是否能诱导动物免疫应答及抵抗眼角膜单纯疱疹病毒Ⅰ型（HSV-1）的感染。方法：提取HSV-1基因组DNA，PCR扩增获得gC基因。以pRSC-gD-IL-21质粒为模板（本实验室2011年构建），构建重组质粒pRSC-gD.gC-IL-21，用纳米材料壳聚糖（chitosan）包裹，采用黏膜接种的方式分别以pRSC-gD.gC-IL-21+chitosan、pRSC-gD-IL-21+chitosan、pRSC+chitosan及chitosan免疫小鼠3次，间隔2周，末次免疫2周后检测各项免疫学指标，同时评价小鼠对病毒攻击角膜的免疫保护作用。结果：经测序、酶切及Western blot鉴定，重组质粒pRSC-gD.gC-IL-21构建成功，chitosan包裹率高。与对照鼠相比，该疫苗在鼠体内产生了更强的特异性中和抗体、细胞毒性T淋巴细胞（CTL）及自然杀伤细胞（NK）杀伤活性增强、泪液中特异性sIgA水平增高，同时使小鼠产生了较强的针对眼角膜HSV-1感染的免疫保护作用。结论：DNA疫苗pRSC-gD.gC-IL-21构建成功，能诱导小鼠产生较强的免疫应答及针对HSV-1眼部感染的免疫保护作用，能够预防单纯疱疹病毒性角膜炎（HSK）的发生、发展。

Objective: To construct DNA vaccine pRSC-gD.gC-IL-21 and to investigate its ability to induce immune response and resist the herpes simplex virus type 1(HSV-1) infection of cornea in mice. Methods: HSV-1 genomic DNA was extracted and the gene of gC was amplified by PCR. As a template with pRSC-gD-IL-21 plasmid(in 2011, our laboratory has been building successful), DNA vaccine pRSC-gD.gC-IL-21 was constructed. After being identifed by molecular methods, we packaged them with nanometer materials chitosan. With the method of mucosal immunization, the vaccine pRSC-gD.gC-IL-21+chitosan, the pRSC-gD-IL-21+chitosan, the blank pRSC+chitosan and the chitosan were respectively inoculated into BALB/c mice for 3 times with 2 weeks interval. A number of immunological indexes were detected 2 weeks after the last immunization. At the same time, the immunoprotective against HSV-1 challenging on cornea in mice was also evaluated. Results: By DNA sequencing, the restricted endonuclease analysis, and Western blot expression, the construction of DNA vaccine pRSC-gD.gC-IL-21 was proved to be constructed successful, and chitosan package rate was high. Compared with the control mice, the DNA vaccine induced the mice to generate higher levels of antibody, enhanced the splenic cell proliferation response as well as the activities of cytotoxic T lymphocyte(CTL)cell and natural killer(NK) cell, and increased the specificity sIgA levels in tears. Meanwhile, the pRSC-gD.gC-IL-21+chitosan could elicit a stronger immunoprotective effect against the corneal infection of HSV-1 in mice. Conclusion: The construction of DNA vaccine pRSC-gD.gC-IL-21 is successful. The DNA vaccine pRSC-gD.gC-IL-21 may induce an effective immune response in immunized mice. More importantly, the efficacy against the HSV-1 challenge in mouse cornea is enhanced markedly. It can prevent the occurrence and development of the herpes simplex keratitis(HSK).

参考文献：

[1] JOSE G G,LARSEN I V,GAUGER J,et al.A cationic peptide,TAT-Cd°,inhibits herpes simplex virus type 1 ocular infection in vivo[J].Invest Ophthalmol Vis Sci,2013,54(2):1070-1079.
[2] HU K,DOU J,YU F L,et al.An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herps simplex virus type 1 in mice[J].Vaccine,2011,29(7):1455-1462.
[3] PIRET J,BOIVIN G.Resistance of herpes simplex vivuses to nucleoside analogues:mechanisms,prevalence,and management[J].Antimicrob Agents Chemother,2011,55(2):459-472.
[4] BRANS R,YAO F.Immunization with a dominant-negative recombinant herpes simplex virus(HSV)type 1 protects against HSV-2 genital disease in guinea pigs[J].BMC Microbiol,2010,10:163.
[5] ALLEN S J,MOTT K R,ZANDIAN M,et al.Immunization with different viral antigens alters the pattern of T cell exhaustion and latency in herpes simplex virus type 1-infected mice[J].J Virol,2010,84(23):12315-12324.
[6] HAZLETT L D,HENDRICKS R L.Reviews for immune privilege in the year 2010:immune privilege and infection[J].Ocul Immunol Inflamm,2010,18(4):237-243.
[7] HOOK L M,HUANG J L,JIANG M,et al.Blocking antibody access to neutralizing domains on glycoproteins involved in entry as a novel mechanism of immune evasion by herpes simplex virus type 1 glycoproteins C and E[J].J Virol,2008,82(14):6935-6941.
[8] GASPAR V M,MOREIRA A F,COSTA E C,et al.Gas-generating TPGS-PLGA microspheres loaded with nanoparticles(NIMPS)for co-delivery of minicircle DNA and anti-tumoral drugs[J].Colloids Surf B,2015,134:287-294.
[9] 何亮,甄勇,张恒柱,等.新型温度敏感水凝胶作为动脉瘤栓塞材料的初步研究[J].东南大学学报:医学版,2016,35(1):63-67.
[10] 张磊,丁琪,夏扬,等.掺杂F₃O₄磁性纳米粒子壳聚糖凝胶的制备及其性质研究[J].东南大学学报:医学版,2012,31(5):567-571.
[11] PRABAHARAN M.Chitosan-based nanoparticles for tumor-targeted drug delivery[J].Int J Biol Macromol,2015,72:1313-1322.
[12] TAPAS K M,SHINYA T,SEWON K,et al.Functional Silencing of TATA-binding protein(TBP)by a covalent linkage of the N-terminal domain of TBP-associated Factor 1[J].J Biol Chem,2007,282(30):22228-22238.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录